Health Care [ 5/12 ] | Biotechnology [ 39/75 ]
NASDAQ | Common Stock
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.
Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.
In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors.
The company was incorporated in 2011 and is headquartered in Suzhou, China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 3, 25 | 0.00 Decreased by N/A% | -0.18 Increased by +100.00% |
| Aug 12, 25 | -0.23 Increased by +19.30% | -0.33 Increased by +30.30% |
| May 28, 25 | -0.17 Decreased by N/A% | -0.17 |
| Mar 24, 25 | -0.29 Decreased by -7.41% | -0.47 Increased by +38.30% |
| Nov 27, 24 | 0.00 Increased by +100.00% | - |
| Jul 25, 24 | -0.28 Increased by +80.74% | -0.26 Decreased by -9.62% |
| May 29, 24 | 0.00 Increased by +100.00% | - |
| Mar 29, 24 | -0.27 Increased by +82.58% | -0.27 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | N/A Decreased by N/A% | -13.51 M Decreased by -58.84% | - - |
| Dec 31, 24 | 103.20 K Decreased by -74.70% | -24.92 M Decreased by -235.88% | Decreased by -24.14 K% Decreased by -1.23 K% |
| Sep 30, 24 | N/A Decreased by -100.00% | -8.51 M Decreased by -14.65% | - - |
| Jun 30, 24 | N/A Decreased by -100.00% | -8.51 M Decreased by -314.03% | - - |
| Mar 31, 24 | N/A Decreased by -100.00% | -8.51 M Decreased by -314.03% | - - |
| Dec 31, 23 | 407.87 K Increased by +N/A% | -7.42 M Decreased by N/A% | Decreased by -1.82 K% - |
| Sep 30, 23 | 407.87 K Decreased by -84.81% | -7.42 M Increased by +54.10% | Decreased by -1.82 K% Decreased by -202.10% |
| Jun 30, 23 | 8.65 M Increased by +120.43% | -2.05 M Increased by +95.69% | Decreased by -23.76% Increased by +98.04% |